Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences
MJH Life Sciences

SUBSCRIBE: Print / eNewsletter

Personalized Peptide Vaccine Prolongs Survival in Bladder Cancer

  • Dave Levitan
December 4, 2015
  • Bladder Cancer, Genitourinary Cancer Targets, Genitourinary Cancers

The use of a personalized peptide vaccination (PPV) failed to improve progression-free survival (PFS) in patients with chemotherapy-resistant advanced urothelial bladder cancer, though overall survival (OS) was significantly better, according to a randomized, open-label, phase II trial.

Though urothelial bladder cancer is generally sensitive to chemotherapy, most patients will progress on platinum-based regimens and survival is limited, wrote study authors led by Masanori Noguchi, MD, PhD, of the Kurume University School of Medicine in Kurume, Japan. The researchers have developed a novel immunotherapeutic approach to second-line therapy, in which at most 4 human leukocyte antigen (HLA)-matched peptides are selected out of a pool of 31 peptides. The selection is based upon both HLA type and pre-existing host immunity prior to vaccination.

In this trial, 80 patients with progressive bladder cancer who had previously received platinum-based chemotherapy were randomized to either PPV plus best supportive care (BSC, 39 patients) or to BSC alone (41 patients). The results were published online ahead of print in Clinical Cancer Research.

The primary endpoint of the study was not met, with a median PFS of 2 months with PPV and 1.8 months with BSC. This yielded a hazard ratio for progression of 0.7 (95% confidence interval [CI], 0.4–1.2; P = .17).

At the time of data cutoff, 74% of the full cohort had died due to their disease. OS was in fact better with PPV, with a median of 7.9 months vs 4.1 months for BSC, for an HR of 0.58 (95% CI, 0.34–0.99; P = .049).

The most common adverse events in the PPV group were dermatologic reactions at injection sites in 91% of patients, abdominal pain in 34%, and increased creatinine levels in 34%. In the BSC group, abdominal pain (41%), peripheral edema (38%), and anemia (38%) were common. Almost all events were grades 1 or 2, and none of 32 grade 3 events were deemed related to treatment.

“This study is, to our knowledge, the first randomized phase II study investigating the efficacy of PPV treatment in patients with metastatic bladder cancer after failure of platinum-based regimens, and showed longer survival after cancer vaccination than BSC treatment,” the authors wrote.

They hypothesized that an advantage of PPV may be an ability to stimulate effector T cells for a faster and stronger immune response, as compared to a conventional peptide vaccine. “Because this study is a small scale of randomized clinical study, further investigation of PPV in advanced or metastatic urothelial cancer is warranted,” they concluded.

Related Articles

  • AZGP1 in Localized Prostate Cancer Associated With Relapse Outcomes
  • Do Antibiotics Impair Efficacy of Immunotherapy in Kidney Cancer?
  • Can Liquid Biopsies and Tumor Biomarkers Personalize Prostate Cancer Treatment?
  • FDA Approves New Drug for Bladder Cancer
  • Cabozantinib Receives FDA Approval for Treating Advanced RCC

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Breast Cancer
  • Acute Myeloid Leukemia
  • HER2-Positive Breast Cancer
  • Videos Breast Cancer
  • Follicular Lymphoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

ONCOLOGY Vol 33 No 11
Nov 21, 2019 Vol 33 No 11
Subscribe
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".